TICKER INTELLIGENCE
$BDX is a publicly traded company in the Healthcare sector. This company operates across Healthcare and is subject to various Congressional legislative and regulatory actions. HillSignal is tracking 2 active Congressional signals mentioning $BDX, including 2 bills. The current legislative sentiment is predominantly bullish, suggesting potential tailwinds from government policy.
$BDX is currently facing 2 active congressional signals tracked by HillSignal. With 2 bullish, and 0 bearish signals, the average legislative impact score is 5.0/10. Key sectors affected include Healthcare and Technology. Recent major catalysts include Ensuring Patient Access to Critical Breakthrough Products Act and SEPSIS Act. Below is the complete tracker of government activity affecting $BDX’s market performance.
2
Total Signals
5.0/10
Avg Impact
2
Bullish Signals
0
Bearish Signals
HR5343 would force Medicare to provide immediate 4-year coverage for FDA breakthrough devices, directly benefiting large medical device manufacturers by eliminating the current 1-3 year coverage lag. The bill passed the Ways & Means committee 37-3 but awaits floor action. Despite bearish recent price action (MDT -8.2%, ABT -11%, BDX -7.3% in 30 days), this bill represents a structural catalyst for device revenue acceleration.
The SEPSIS Act (S.1929) is an early-stage authorization bill that would create federal programs for sepsis research, education, and data collection. It authorizes but does not appropriate funding, and with only 6 cosponsors and referral to committee in June 2025, passage remains uncertain. Real market data shows all four diagnostic/lab stocks have declined 1-6% in the past week and 2-10% over 30 days, reflecting broader market pressure on healthcare despite the legislative catalyst.
Daily AI-analyzed alerts for Congressional activity affecting your portfolio.
Get Started →